https://www.selleckchem.com/pr....oducts/muvalaplin.ht
Average percent root coverage for CTG+CAF was 90.5% ± 14.87%versus 70.7% ± 28.26% for VCMX+CAF, P0.0001. Both therapies produced significant soft tissue volume increases (84.8 ± 47.43 mm control versus 48.90 ± 35.58 mm test, P=0.0006). The test, harvest graft substitute produced less postoperative pain and was preferred by patients at the 6-month end point. All other end point measures were not significantly different. VCMX+CAF root coverage was inferior to CTG+CAF but produced less morbidity and was preferred by patients. Case/p
Like
Comment
Share
